Denmark· DK-28106033517
Octreoanne
A octreotide product containing octreotidacetat, registered in Denmark by Teva B.V.. The same ATC class is registered in 17 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Octreotide is registered in 17 of 19 countries.
Countries holding a registration under ATC H01CB02 (octreotide), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 10 of them publish a price we can compare per daily dose
Octreotide · ATC H01CB02
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of octreotide costs, country by country.
Normalised to the WHO defined daily dose (0.7 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Octreotide · price per daily dose (0.7 mg)
USD · FX 28 Sept 2026
- CH Switzerland$41.46
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- OCTREOTIDACETAT
- Manufacturer
- Teva B.V.
- Country
- Denmark (DK)
- ATC code
- H01CB02
- ATC class
- Octreotide
- Defined daily dose
- 0.7 mg, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106033517
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
367 interactions on record for octreotide.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Octreotide · interactions on record
367 records
- 4 severe
- 151 moderate
- 4 minor
- 168 info
Most severe, free to view
- LonafarnibA16AX20severe
- PexidartinibL01EX15severe
- BexaroteneL01XF03severe
- BexarotenL01XX25severe
40 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under H01CB02
Octreotide, as other registers publish it.
- United StatesBYNFEZIA PenSun Pharmaceutical Industries, Inc.
- IrelandEzetimibe/Simvastatin Teva Pharma 10 mg/20 mg tabletsTeva B.V.
- IrelandEzetimibe/Simvastatin Teva Pharma 10 mg/80 mg tabletsTeva B.V.
- FinlandMycapssaAmryt Pharmaceuticals DAC
- United StatesMycapssaChiesi USA, Inc.
- United StatesMycapssaAmryt Pharmaceuticals Designated Activity Company
- PolandMycapssaAmryt Pharmaceuticals DAC
- BelgiumMycapssa 20 mgAmryt Pharmaceuticals DAC
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d965e9f3-3762-4107-a61c-464aa611fc0d GET /v1/drugs/d965e9f3-3762-4107-a61c-464aa611fc0d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "pulver og solvens til depotinjektionsvæske, suspension",
"source": "dkma",
"strength": "10 mg",
"auth_role": "CMS",
"dk_drugid": "28106033517",
"substance": "OCTREOTIDACETAT",
"auth_procedure": "Decentral procedure",
"in_medicinpriser": true,
"registration_date_serial": "43595"
}See everything about octreotide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.